World's Best Scientists 2026 revealed!
Allan H. Friedman

Allan H. Friedman

D-Index & Metrics

Medicine

D-Index
117
Citations
61786
World Ranking
4153
National Ranking
2278

Overview

Allan H. Friedman is affiliated with Duke University in the United States. Their research primarily spans the field of Medicine, with a focus on multiple subfields including Neurology, Genetics, Radiology, Nuclear Medicine and Imaging, Cognitive Neuroscience, and Epidemiology.

The scientist's work covers key topics such as Glioma Diagnosis and Treatment, Meningioma and Schwannoma Management, EEG and Brain-Computer Interfaces, Cancer Immunotherapy and Biomarkers, Neuroscience and Neural Engineering, Toxin Mechanisms and Immunotoxins, and Monoclonal and Polyclonal Antibodies Research.

Frequent co-authors include Annick Desjardins, James E. Herndon, David M. Ashley, Henry S. Friedman, and Mustafa Khasraw.

Publications have appeared mostly in the following venues:

  • Neuro-Oncology
  • Acta Neurochirurgica
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Clinical Oncology
  • Journal of Neurological Surgery Part B Skull Base

Recent significant papers authored or co-authored by Allan H. Friedman include:

  • "Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy" (2021), published in Nature Communications
  • "High-resolution neural recordings improve the accuracy of speech decoding" (2023), published in Nature Communications
  • "Flexible, high-resolution thin-film electrodes for human and animal neural research" (2021), published in Journal of Neural Engineering
  • "Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial" (2023), published in The Lancet Child & Adolescent Health
  • "Intraoperative microseizure detection using a high-density micro-electrocorticography electrode array" (2022), published in Brain Communications

Best Publications

  • Comprehensive genomic characterization defines human glioblastoma genes and core pathways

    Roger McLendon;Allan Friedman;Darrell Bigner;Erwin G. Van Meir

  • IDH1 and IDH2 Mutations in Gliomas

    Hai Yan;D. Williams Parsons;Genglin Jin;Roger McLendon

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

    Patrick J. Killela;Zachary J. Reitman;Yuchen Jiao;Chetan Bettegowda

  • Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jeannette M. Dowell

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse

    W. K.Alfred Yung;Michael D. Prados;Ricardo Yaya-Tur;Steven S. Rosenfeld

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • Recurrent glioblastoma treated with recombinant poliovirus

    Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier

  • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

    Peter E. Fecci;Duane A. Mitchell;John F. Whitesides;Weihua Xie

  • Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

    Yuchen Jiao;Patrick J. Killela;Zachary J. Reitman;B Ahmed Rasheed

  • Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.

    Brem H;Mahaley Ms;Vick Na;Black Kl

  • Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma

    John H. Sampson;James H. Carter;Allan H. Friedman;Hilliard F. Seigler

  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

    Duane A. Mitchell;Kristen A. Batich;Michael D. Gunn;Min-Nung Huang

  • PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

    B. K. Ahmed Rasheed;Timothy T. Stenzel;Roger E. McLendon;Ramon Parsons

  • Cell Surface Localization and Density of the Tumor-associated Variant of the Epidermal Growth Factor Receptor, EGFRvIII'

    Carol J. Wikstrand;Roger E. McLendon;Allan H. Friedman;Darell D. Bigner

  • DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

    HS Friedman;RE McLendon;T Kerby;M Dugan

  • Subarachnoid hemorrhage from intracranial dissecting aneurysm

    Allan H. Friedman;Charles G. Drake

  • TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL

    Hai Yan;P.J. Killela;Z.J. Reitman;Y. Jiao

  • Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

    Duane A. Mitchell;Weihua Xie;Robert Schmittling;Chris Learn

Frequent Co-Authors

Henry S. Friedman
Henry S. Friedman Duke University
Darell D. Bigner
Darell D. Bigner Duke University
John H. Sampson
John H. Sampson Duke University
James E. Herndon
James E. Herndon Duke University
Roger E. McLendon
Roger E. McLendon Duke University
David A. Reardon
David A. Reardon Harvard University
James J. Vredenburgh
James J. Vredenburgh Yale School of Medicine
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh
James M. Provenzale
James M. Provenzale Duke University
Gary E. Archer
Gary E. Archer Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always have to mean medical school. There are several flexible online pathways for students interested in healthcare careers. Online PhD programs in nursing offer advanced opportunities for nurses looking to specialize, conduct research, or move into academic leadership roles—all with the flexibility of remote study.

For those just beginning, online ADN programs are a practical way to earn an associate degree and become a registered nurse. Many students later advance their credentials through bridge options, such as cheapest BSN programs that fit around work and family obligations.

If you hold a non-nursing bachelor’s degree, direct entry MSN programs online allow you to transition into nursing at the graduate level, preparing you for leadership, advanced practice, or specialized roles. Each of these options makes healthcare careers more accessible, affordable, and convenient for diverse learners.

Best Scientists Citing Allan H. Friedman

Trending Scientists

Recently Published Articles